Product Offerings - The company reported a significant focus on men's wellness telemedicine services, particularly in erectile dysfunction, hair loss, testosterone replacement, and weight management treatments[88] - The Mango ED product includes either Sildenafil (50 mg or 100 mg) or Tadalafil (10 mg or 20 mg), Oxytocin (100 IU), and L-Arginine (50 mg) and is produced under an exemption from FDA approval[88] - The Mango GROW product contains Minoxidil (2.5 mg), Finasteride (1 mg), Vitamin D3 (2000 IU), and Biotin (1 mg), also produced without FDA approval[88] - The MOJO product includes DHEA (10 mg), Pregnenolone (5 mg), and Enclomiphene Citrate (25 mg), produced under the same FDA exemption[89] - The PRIME product, an FDA-approved oral Testosterone Replacement Therapy, is designed to treat low testosterone levels and has shown 96% efficacy by day 90 in clinical trials[89] - The SLIM product contains Vitamin B6 (10 mg) and Semaglutide in varying dosages (0.5 mg to 2.0 mg), produced without FDA approval[90] - The TRIM product includes Tirzepatide in dosages of 3 mg, 4 mg, or 5 mg, also produced under the FDA exemption[90] - The company is expanding its product offerings to include innovative formulations aimed at addressing various health concerns in men[88] - Future pharmaceutical products are planned to be developed under the same regulatory exemptions, allowing for flexibility in product formulation[88] - The company emphasizes the importance of physician determination for the necessity of compounded drugs for individual patients[88] Financial Performance - Revenues for the three months ended September 30, 2024, were $133,368, a decrease of $111,792 or 45.6% compared to $245,160 for the same period in 2023, due to migration issues to a new telehealth platform[98] - Gross profit for the three months ended September 30, 2024, was $82,671, down from $144,589 in 2023, attributed to decreased revenue and increased shipping costs[98] - The company reported a net loss of $1,999,694 for the quarter ended September 30, 2024, an increase of $200,234 or 11.1% from the net loss of $1,799,460 in the same quarter of 2023[99] - For the nine months ended September 30, 2024, revenues increased by $23,507 or 4.8% to $510,626 compared to $487,119 for the same period in 2023, driven by increased digital marketing efforts and recurring subscriptions[100] - Cost of revenues for the nine months ended September 30, 2024, was $71,965, down from $101,538 in 2023, while related party costs increased to $138,800 from $96,663[100] - Total general and administrative expenses for the nine months ended September 30, 2024, were $6,594,193, a decrease of $345,568 from $6,939,761 in 2023[100] - The company reported a net loss of $6,758,630 for the nine months ended September 30, 2024, compared to a net loss of $6,644,370 for the same period in 2023, representing a decrease in net loss of $114,260 or 1.7%[104] - Cash and cash equivalents decreased to $73,912 as of September 30, 2024, from $739,006 as of December 31, 2023, primarily due to funds used for general operating expenses[105] - Total current liabilities amounted to $1,391,382 as of September 30, 2024, including $707,519 in accounts payable and accrued liabilities[105] - The company had a working deficit of $1.3 million and a total accumulated deficit of $17,985,966 as of September 30, 2024[106] - Cash used in operating activities was $3,734,201 for the nine months ended September 30, 2024, mainly due to the net loss of $6,758,630[110] - Cash provided by financing activities was $3,005,770 for the nine months ended September 30, 2024, primarily from $2,250,000 in proceeds from the sale of preferred stock[110] - Stock-based compensation increased to $1,881,464 for the nine months ended September 30, 2024, compared to $1,367,134 for the same period in 2023[102] - Advertising and marketing expenses decreased to $1,332,957 for the nine months ended September 30, 2024, from $1,633,528 in 2023, reflecting a reduction in marketing efforts[102] - The company has experienced recurring net losses since inception and anticipates substantial operating expenses in the foreseeable future[108] Strategic Initiatives - The company entered into a Patent Purchase Agreement for $20,000,000, including 980,000 shares of Series C Preferred Stock valued at $19,600,000 and $400,000 in cash payments[93] - A Master Distribution Agreement was signed with ISFLST, Inc. for the sale of products in Asia Pacific and Latin America, with a term of three years and potential for exclusivity based on milestones[94] - The company plans to continue expanding operations and may seek additional funding through equity or debt financing, which could result in significant dilution for existing shareholders[95] - The company intends to utilize newly acquired patents for research and development of oral applications, including dissolvable tablets and mouthwash[93] - The company is currently evaluating strategic alternatives, which may include business combinations or asset sales, with no definitive timetable set for completion[108] Capital Raising Activities - The company completed its IPO on March 23, 2023, selling 83,334 shares at $60.00 per share, generating approximately $5 million in gross proceeds[111] - A Follow On Offering on December 19, 2023, resulted in the sale of 266,667 shares for total gross proceeds of $1.2 million, with net proceeds of approximately $1.0 million after expenses[112] - The underwriters exercised their over-allotment option on January 22, 2024, resulting in an additional sale of 40,000 shares, generating net proceeds of approximately $160,000[112] - The company entered into a Securities Purchase Agreement on April 5, 2024, to sell 1,500 shares of Series B Convertible Preferred Stock for $1,650,000 and warrants for an aggregate purchase price of $1,500,000[114] - The total proceeds from the Series B Preferred Stock sales, including all closings, are expected to reach $2.75 million, with 320,000 warrants issued[115] - The company issued warrants for the purchase of common stock at various exercise prices, including $5.70 and $0.50, with terms of five years[113][116] - The company is prohibited from issuing additional shares or entering into agreements for new equity financing for a specified period following the closings under the Securities Purchase Agreement[116] - The company has reserved 50,000,000 shares of common stock for the exercise of warrants and conversion of Series B Preferred Stock[116] - The company plans to use proceeds from offerings for marketing, operational expenses, and general corporate purposes[112] - The Company has sold a total of 230,000 shares for gross proceeds of $999,667 under the ELOC, before fees, discounts, and expenses[120] - The Company entered into an Equity Purchase Agreement with the Purchaser to purchase up to $25,000,000 of common stock, with an initial issuance of 66,667 shares as a commitment fee[118] - The floor price of the Series B Preferred Stock was increased from $0.525 per share to $2.25 per share[119] - The Company is required to file a resale registration statement with the SEC within 30 days of the Closing Date, with certain penalties for non-compliance[118] - The ELOC terminates upon the earlier of April 4, 2026, or when $25,000,000 in Advance Shares have been purchased[120] - The Company anticipates needing additional funding to support operations over the next 12 months, which may lead to shareholder dilution[121] - The Registration Statement for the Advance Shares was declared effective on May 9, 2024[120] - The Company has obligations to indemnify the Purchaser and cover all fees related to the ELOC RRA[121] - The Company maintains a share reserve while the ELOC is effective but is not obligated to sell any Advance Shares[120] Accounting and Compliance - The Company has implemented all new accounting pronouncements that may impact its financial statements and does not foresee any material impact from recent accounting standards[124] - The FASB issued ASU No. 2023-07, effective for annual periods beginning after December 15, 2023, requiring additional disclosures on reportable segment expenses and the Chief Operating Decision Maker's role[127] - ASU No. 2023-09 was issued in December 2023, mandating disaggregated information on effective tax rate reconciliation and income taxes paid, effective for annual periods beginning after December 15, 2024[127] - The company is currently evaluating the provisions of ASU No. 2023-07 and expects to adopt them for the year ending December 31, 2024[127] - The adoption of the new accounting standards will likely result in additional required disclosures in the consolidated financial statements[127] - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[128]

Company Overview - Mangoceuticals, Inc. focuses on developing, marketing, and selling men's health and wellness products through a secure telemedicine platform [5] - The company has identified men's wellness telemedicine services, particularly in erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management, as a growing sector [5] - Consumers can utilize MangoRx's telemedicine platform for prescription requests, which are reviewed by a physician and fulfilled through a partner compounding pharmacy [5] Event Participation - Mangoceuticals, Inc. will present at the Centurion One Capital 2nd Annual Bahamas Summit on October 23, 2024, at 11:10 EDT [1] - The summit will feature presentations from various public and private companies to prominent investors from Canada, the United States, and abroad [2] - The event will include presentations, Q&A sessions, panel discussions, and one-on-one investor meetings [3] Event Details - The Centurion One Capital 2nd Annual Bahamas Summit will take place on October 22-23, 2024, at the Rosewood Baha Mar Hotel [3] - The summit will run from 9:00 AM EDT to 4:00 PM EDT each day [3] - Centurion One Capital is an independent investment banking firm dedicated to supporting the growth of companies in North America [3]

Financial Results - Mangoceuticals, Inc. reported financial results for the three and six months ended June 30, 2024[3]. - The press release regarding financial results was issued on August 15, 2024[3]. - The financial results are not deemed "filed" under the Securities Exchange Act of 1934[3]. Company Classification - The company is classified as an emerging growth company under the Securities Act[2]. - The trading symbol for the common stock is MGRX, listed on the Nasdaq Capital Market[2]. Forward-Looking Statements - The report includes forward-looking statements that may involve risks and uncertainties affecting future performance[5]. - The company has no obligation to update or revise forward-looking statements after the date they are made[5]. - The report includes cautionary statements regarding potential factors affecting financial results[5]. Company Information - The company’s principal executive office is located in Dallas, Texas[1]. - The company’s IRS Employer Identification Number is 87-3841292[1].

Core Viewpoint - Mangoceuticals, Inc. has reported significant growth in shareholder equity and gross revenues for the first half of 2024, driven by strategic acquisitions and product innovations in the men's health and wellness sector [1][2][3]. Financial Performance - Shareholder equity increased to $13,829,445 as of June 30, 2024, up 1,685% from $774,754 at the end of 2023, largely due to the acquisition of a global patent portfolio from Intramont Technologies [2]. - Gross revenues for the six months ended June 30, 2024, reached $377,258, representing a 55.92% increase from $241,959 in the same period of 2023 [3]. - Gross profit for the same period was $217,190, a 50.48% increase from $144,329 year-over-year [3]. Strategic Initiatives - The company is focusing on innovation and customer satisfaction, with expectations for further growth in the second half of the year supported by ongoing product development and market expansion [4]. - Upcoming product launches include compounded oral dissolvable tablets for weight loss and hormone therapy products aimed at treating low testosterone, which are anticipated to drive additional revenue growth [4]. Market Positioning - MangoRx is positioned in the growing sector of men's health and wellness, particularly in areas such as erectile dysfunction, hair growth, and hormone replacement therapies [5]. - The company utilizes a secure telemedicine platform to facilitate prescription requests and product fulfillment, enhancing customer experience [5].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41615 | --- | --- | --- | |----------------------------------------------------------------------------------------------------- ...

Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a leader in men's health and wellness products including erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce the initiation of efficacy studies on its patented respiratory illness prevention technology in collaboration with Vipragen Biosciences and IntraMont Technologies, Inc. Notably, these trials have been pre-funded, ensuring that the ...

"We are thrilled to be featured on Benzinga All-Access and to share our vision and plans with a wider audience," said Jacob Cohen. "Our commitment to innovation, quality, and global growth is stronger than ever. We are excited about the future and the opportunities that lie ahead as we continue to expand our product offerings and reach new markets." CLICK HERE TO WATCH THE COMPLETE INTERVIEW. Cautionary Note Regarding Forward-Looking Statements Follow MangoRx on social media: Mangoceuticals Investor Relatio ...

In the interview with Zunaid Suleman, Cohen discussed Mangoceuticals' strategic direction, recent developments, expanding product offerings, and plans for global expansion. He emphasized the company's commitment to innovation and excellence in the health and wellness industry, highlighting the launch of new products designed to meet the evolving needs of consumers worldwide. Cohen also provided insights into the significant growth opportunities within the health and wellness sector, particularly in emerging ...

Amanda Hammer, COO of MangoRx, highlights the system's transformative impact and the significance of the DEA approval: "This authorization through Surescripts marks a pivotal moment for MangoRx. Our system is now capable of supporting hyper growth and has the limitless ability to add new and innovative products. This ensures that we remain at the cutting edge of the telemedicine industry, delivering exceptional value to our patients and stakeholders, all at the same time of maintaining security and regulato ...

Jacob Cohen, CEO and Co-Founder of MangoRx commented, "We anticipate exponential growth in our subscriber base with the launch of MangoRx's new operating system. Our unique proprietary operating system, in development for nearly a year, is designed to revolutionize patient management. Patients can now seamlessly manage their MangoRx doctor visits, prescription auto-refills, and overall health with unprecedented ease and security. This milestone underscores our dedication to leveraging technology for superio ...